The global single-photon emission computed tomography market is on a path of significant growth, driven by cutting-edge advancements in diagnostic imaging technologies and the increasing prevalence of cardiovascular diseases. According to recent market analysis, the SPECT market, which was valued at USD 2.28 billion in 2021, is estimated to have reached USD 2.45 billion by the end of 2022, reflecting a strong upward trajectory.
This growth trend is expected to continue, with the SPECT market projected to expand at a compound annual growth rate (CAGR) of 6.9% over the forecast period from 2022 to 2032. By the close of this period, the global market is anticipated to reach an impressive USD 4.76 billion, underscoring a robust and sustained demand for SPECT technology.
SPECT is a crucial nuclear medicine technique that enables three-dimensional imaging of functional processes within the human body. It relies on short-lived radioisotopes for non-invasive diagnostic imaging, making it an essential tool in detecting and managing chronic illnesses. Its ability to provide detailed insights into metabolic processes is pivotal in diagnosing a wide range of diseases, including cardiovascular disorders, neurological conditions, and cancer.
In 2021, the single imaging gamma cameras segment dominated the global SPECT market with a substantial market share of 75.5%. This segment is expected to maintain its leadership throughout the forecast period, as gamma cameras play a vital role in enhancing the diagnostic capabilities of SPECT systems by providing detailed metabolic and functional data of cells and organs.
The rising demand for more accurate and efficient diagnostic tools, along with advancements in organ-specific and dual-modality imaging systems, is a key factor driving the expansion of the SPECT market. As healthcare providers prioritize the need for precision diagnostics, SPECT technology is positioned to meet these requirements, offering enhanced imaging solutions that improve patient outcomes.
FMI, a leading market analyst, stated, “The global SPECT market is witnessing robust growth driven by technological advancements and the rising burden of cardiovascular diseases. As we move towards 2032, innovations in imaging systems and enhanced diagnostic capabilities will further accelerate market expansion.”
With continued advancements in SPECT technology, the future looks promising for the market, offering healthcare providers and patients access to more accurate, non-invasive diagnostic solutions that can significantly improve disease management.
Key Takeaways: Single-Photon Emission Computed Tomography (SPECT) Market
- The global SPECT market reached USD 2.28 billion in 2021 and is expected to reach USD 2.45 billion by 2022.
- The market is expected to grow at a CAGR of 6.9% from 2022 to 2032, reaching a valuation of USD 4.76 billion by 2032. This growth is attributed to the rising prevalence of cardiovascular diseases and the demand for better diagnostic tools.
- North America, with the USA holding a dominant 38% share in 2021, is expected to continue leading the market due to favorable reimbursement policies for nuclear medicine procedures.
- China’s SPECT market, with a 5.3% share in 2021, is projected for healthy growth due to advancements in medical infrastructure, focus on chronic disease management, and government support for cancer research.
- Germany, with an aging population and increasing use of radiopharmaceutical diagnostics, is expected to hold a nearly 5% market share due to government funding initiatives.
Stay Ahead with Single-Photon Emission Computed Tomography: Delve into Our Full Report for Extensive Trends and Insights!
Competitive Landscape:
Major players in the single-photon emission computed tomography (SPECT) market are aggressively pursuing market dominance through strategic partnerships, product launches, and expansion efforts. For example:
- In November 2020, GE Healthcare acquired Prismatic Sensors AB, a Swedish startup known for its expertise in photon-counting detectors. This acquisition underscores GE Healthcare’s ongoing commitment to advancing photon-counting CT technology.
- In May 2022, Mediso Ltd. acquired Bartec Technologies Ltd., a UK-based company specializing in the supply, installation, and support of Nuclear Medicine and Molecular Imaging equipment and accessories.
These moves highlight the proactive strategies employed by industry leaders to strengthen their positions and drive innovation in the SPECT market.
Key Companies Profiled:
- Bruker Corp.
- DDD-Diagnostic AS
- Digmed Corp.
- General Electric Co.
- Mediso Ltd.
- MiE GmbH
- MILabs BV
- Siemens Healthineers AG
- Spectrum Dynamics Medical Inc.
- GE Healthcare
- CardiArc
- Beijing Hamamatsu Photon Techniques INC.
- SHENZHEN BASDA MEDICAL APPARATUS CO., LTD.
- PNPMed
- NuCare Inc.
Key Market Segments Covered in Single-photon Emission Computed Tomography Industry Research:
By Product:
- Single Imaging Gamma Cameras
- SPECT/CT
By Application:
- Cardiology
- Oncology
- Neurology
- Others
By End User:
- Hospitals
- Diagnostic Imaging Centers
- Ambulatory Surgical Centers
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa(MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
